Orion - Company Announcement

Orion upgrades full-year outlook for 2010

ORION CORPORATION          STOCK EXCHANGE RELEASE          14 June 2010 at
10:15 EET


The positive earnings development reported by the Orion Group for the first
quarter of 2010 has continued showing similar performance also in the second
quarter. Despite the increasingly tightened situation on the market, sales have
shown continued positive development whereas costs have remained at the previous
year's level. In the light of the current development, the Board of Directors of
Orion Corporation has decided to change the full-year outlook estimate for 2010
provided in the Interim Report 1-3/2010 and published on 27 April 2010. The
basis for the outlook remains the same as that for the outlook provided in the
Interim Report 1-3/2010 published on 27 April 2010.



New full-year outlook estimate for 2010, provided on 14 June 2010

Net sales will be higher than in 2009.



Marketing expenditure will be higher due to the increased number of product
launches and the expansion of operations to Southern Europe. Research
expenditure will be lower than in 2009. The costs of ongoing patent litigation
in the United States are expected to be lower than in 2009.



Operating profit excluding non-recurring items will be higher than in 2009.



The Group's capital expenditure will be about EUR 40 million excluding
substantial corporate or product acquisitions.



Previous full-year outlook for 2010, provided in Interim Report 1-3/2010

Net sales will be slightly higher than in 2009.



Marketing expenditure will be higher due to the increased number of product
launches and the expansion of operations to Southern Europe. Research
expenditure will be slightly lower than in 2009. The costs of ongoing patent
litigation in the United States are expected to be lower than in 2009.



Operating profit excluding non-recurring items will be slightly higher than in
2009.



The Group's capital expenditure will be about EUR 40 million excluding
substantial corporate or product acquisitions.





The Interim Report for 1-6/2010 of the Orion Group will be published on Tuesday,
10 August 2010.





Orion Corporation



Timo Lappalainen, President and CEO

Olli Huotari, SVP, Corporate Functions





Contact person:

Jari Karlson, CFO, phone +358 50 966 2883



Publisher:
Orion Corporation

www.orion.fi/en <http://www.orion.fi/en>





Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, cancer and critical care drugs, and Easyhaler(®)
pulmonary drugs.



The Group's net sales in 2009 amounted to EUR 772 million. The Company invested
EUR 95 million in research and development. At the end of 2009, the Group had a
total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other
European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.


[HUG#1423548]